Profile: CV Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of new small molecule drugs for the treatment of cardiovascular diseases. By exploring the mechanism of cardiovascular disease with molecular cardiology, new opportunities are being created to discover improved therapies. Our marketed products include Ranexa® and Lexiscan®. Ranexa® is indicated for the treatment of chronic angina. This may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. It works by improving blood flow to help the heart work more efficient.